Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lyell ImmunopharmaLYEL +0.94%55 Return-on-Tangible-Asset is -54.10% as of Jun. 2026. GuruFocus rates LYEL with a GF Score™ of 55/100 and a GF Value™ of $3.71 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,412 Biotechnology companies, Lyell Immunopharma ranks worse than 69.97% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Lyell Immunopharma's annualizedNet Income for the quarter that ended in Jun. 2026 was $-179.02 Mil. Lyell Immunopharma's average total tangible assets for the quarter that ended in Jun. 2026 was $330.89 Mil. Therefore, Lyell Immunopharma's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was -54.10%.
The historical rank and industry rank for Lyell Immunopharma's Return-on-Tangible-Asset or its related term are showing as below:
LYEL'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -69.2 Med: -27.81 Max: -17.74
Current: -69.2
During the past 7 years, Lyell Immunopharma's highest Return-on-Tangible-Asset was -17.74%. The lowest was -69.20%. And the median was -27.81%.
LYEL's Return-on-Tangible-Asset is ranked worse than 69.97% of 1412
companies
in the Biotechnology industry
Industry Median: -35.545
vs LYEL: -69.20
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Lyell Immunopharma Return-on-Tangible-Asset Related Terms
Lyell Immunopharma Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Lyell Immunopharma's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LYEL vs FHTX, ZNTL, PALI: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Lyell Immunopharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyell Immunopharma Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyell Immunopharma's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Lyell Immunopharma's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of -54.10% mean?
Lyell Immunopharma (LYEL) has a Return-on-Tangible-Asset of -54.10% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Lyell Immunopharma and its competitors. According to the industry distribution chart, Lyell Immunopharma ranks #988 out of 1412 companies in the Biotechnology industry, placing it in the top 70%.
Is Lyell Immunopharma's Return-on-Tangible-Asset too high?
Lyell Immunopharma's current Return-on-Tangible-Asset is -54.10%. Based on the distribution chart, Lyell Immunopharma ranks #988 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Lyell Immunopharma has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lyell Immunopharma's Return-on-Tangible-Asset compare to FHTX and ZNTL?
According to the Biotechnology industry distribution chart, Lyell Immunopharma ranks #988 out of 1412 companies for Return-on-Tangible-Asset. This places Lyell Immunopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Lyell Immunopharma and its competitors. Lyell Immunopharma's current Return-on-Tangible-Asset is -54.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyell Immunopharma stock overvalued right now?
Based on GuruFocus' analysis, Lyell Immunopharma (LYEL) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.71, compared to a current price of $14.53 — trading 291.6% above its estimated fair value. The current Return-on-Tangible-Asset is -54.10%. Lyell Immunopharma's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Lyell Immunopharma (LYEL), the current Return-on-Tangible-Asset is -54.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyell Immunopharma (LYEL) Overvalued in 2026?
Based on GuruFocus' analysis, Lyell Immunopharma stock appears to be overvalued.
The current stock price of $14.53 is trading 291.6% above its estimated GF Value™ of $3.71.
GuruFocus considers Lyell Immunopharma to be Significantly Overvalued.
Key valuation signals for LYEL:
Return-on-Tangible-Asset: -54.10%
GF Value™: $3.71 vs. price of $14.53 (291.6% above fair value)
No single metric tells the full story. See the LYEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
55GF Score
Get the complete analysis for LYEL
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LYEL has been successfully added to your 
